Tenofovir-Induced Leukocytoclastic Vasculitis
Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocy...
Gespeichert in:
| Veröffentlicht in: | Oman medical journal 2017-09, Vol.32 (5), p.429-431 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 431 |
|---|---|
| container_issue | 5 |
| container_start_page | 429 |
| container_title | Oman medical journal |
| container_volume | 32 |
| creator | Al-Hamadani , Aysha Al-Busafi , Said A Rasool , Wasif Al-Suleimani , Abdulatif |
| description | Tenofovir, a nucleotide analog, is one of the first-line medications recommended for
the treatment of active chronic hepatitis B virus infection (CHB) and as a primary
prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report
the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese
woman, who was known to have inactive CHB, was diagnosed with chronic immune
thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was
put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a
skin rash, described as non-blanchable well-defined erythematous to violaceous papules
and targetoid patches in her lower extremities. A skin biopsy showed features of LCV.
The rash resolved completely within few days after replacing tenofovir with entecavir. |
| doi_str_mv | 10.5001/omj.2017.80 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_pubmed_primary_29026476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><informt_id>10.3316/informit.152783122352702</informt_id><doaj_id>oai_doaj_org_article_887a50e05b5b4c11852c47a6448f0848</doaj_id><sourcerecordid>29026476</sourcerecordid><originalsourceid>FETCH-LOGICAL-a4550-a2ebf086667948a2e7f05a75ee37c38a25881b1956339808c00a9e3a19e7b4a03</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhiMEoqvSE2dQ7yjL-Nu-IKGqlJVW4lJQb9bEcbpekriys5X673Gasm19sT0zft7XM1X1kcBaAJCvcdivKRC11vCmWlFQUAsK_G21IsaYWkl9c1Kd5byHspihhtH31Qk1QCVXclXV136MXbwPqd6M7cH59nzrD3-je5ii6zFPwZ3_wewOfZhC_lC967DP_uxpP61-_7i8vvhZb39dbS6-b2vkQkCN1DcdaCmlMlyXm-pAoBLeM-VYCQitSUOMkIwZDdoBoPEMifGq4QjstNos3Dbi3t6lMGB6sBGDfQzEdGsxFWu9t1orFOBBNKLhjhAtqOMKJee6WOC6sL4trLtDM_jW-XFK2L-Cvs6MYWdv470t7qg0M-DLAnAp5px8d3xLwM5DsGUIdh6C1bP1zy_ljrX_W14KbpaCNITJutj33k0hjnmPU7bZY3I7G8YuPubnr7YxWGzyLMcYkc9JIqjSjFDKygFoQX9a0L5I-g6P4kpzxdizN-wHHHcvukAIAS7ZP5CwtHY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tenofovir-Induced Leukocytoclastic Vasculitis</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Al-Hamadani , Aysha ; Al-Busafi , Said A ; Rasool , Wasif ; Al-Suleimani , Abdulatif</creator><creatorcontrib>Al-Hamadani , Aysha ; Al-Busafi , Said A ; Rasool , Wasif ; Al-Suleimani , Abdulatif</creatorcontrib><description>Tenofovir, a nucleotide analog, is one of the first-line medications recommended for
the treatment of active chronic hepatitis B virus infection (CHB) and as a primary
prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report
the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese
woman, who was known to have inactive CHB, was diagnosed with chronic immune
thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was
put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a
skin rash, described as non-blanchable well-defined erythematous to violaceous papules
and targetoid patches in her lower extremities. A skin biopsy showed features of LCV.
The rash resolved completely within few days after replacing tenofovir with entecavir.</description><identifier>ISSN: 1999-768X</identifier><identifier>EISSN: 2070-5204</identifier><identifier>DOI: 10.5001/omj.2017.80</identifier><identifier>PMID: 29026476</identifier><language>eng</language><publisher>Muscat - Oman: Oman Medical Specialty Board</publisher><subject>Case Report ; Chronic active hepatitis ; DIAGNOSIS ; HEPATITIS ; Hepatitis B ; Leukocytoclastic Vasculitis ; LIVER DISEASES ; PATIENTS ; Prevention ; Tenofovir ; THERAPY ; Thrombotic thrombocytopenic purpura ; VASCULITIS ; أمراض الكبد ; إلتهاب الأوعية ; إلتهاب الكبد ; التشخيص ; العلاج ; المرضى</subject><ispartof>Oman medical journal, 2017-09, Vol.32 (5), p.429-431</ispartof><rights>The OMJ is Published Bimonthly and Copyrighted 2017 by the OMSB. 2017 Oman Medical Specialty Board</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a4550-a2ebf086667948a2e7f05a75ee37c38a25881b1956339808c00a9e3a19e7b4a03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttps://static.almanhal.com/covers/titl/111046/cover-lg.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632698/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632698/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29026476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Hamadani , Aysha</creatorcontrib><creatorcontrib>Al-Busafi , Said A</creatorcontrib><creatorcontrib>Rasool , Wasif</creatorcontrib><creatorcontrib>Al-Suleimani , Abdulatif</creatorcontrib><title>Tenofovir-Induced Leukocytoclastic Vasculitis</title><title>Oman medical journal</title><addtitle>Oman Med J</addtitle><description>Tenofovir, a nucleotide analog, is one of the first-line medications recommended for
the treatment of active chronic hepatitis B virus infection (CHB) and as a primary
prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report
the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese
woman, who was known to have inactive CHB, was diagnosed with chronic immune
thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was
put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a
skin rash, described as non-blanchable well-defined erythematous to violaceous papules
and targetoid patches in her lower extremities. A skin biopsy showed features of LCV.
The rash resolved completely within few days after replacing tenofovir with entecavir.</description><subject>Case Report</subject><subject>Chronic active hepatitis</subject><subject>DIAGNOSIS</subject><subject>HEPATITIS</subject><subject>Hepatitis B</subject><subject>Leukocytoclastic Vasculitis</subject><subject>LIVER DISEASES</subject><subject>PATIENTS</subject><subject>Prevention</subject><subject>Tenofovir</subject><subject>THERAPY</subject><subject>Thrombotic thrombocytopenic purpura</subject><subject>VASCULITIS</subject><subject>أمراض الكبد</subject><subject>إلتهاب الأوعية</subject><subject>إلتهاب الكبد</subject><subject>التشخيص</subject><subject>العلاج</subject><subject>المرضى</subject><issn>1999-768X</issn><issn>2070-5204</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1v1DAQhiMEoqvSE2dQ7yjL-Nu-IKGqlJVW4lJQb9bEcbpekriys5X673Gasm19sT0zft7XM1X1kcBaAJCvcdivKRC11vCmWlFQUAsK_G21IsaYWkl9c1Kd5byHspihhtH31Qk1QCVXclXV136MXbwPqd6M7cH59nzrD3-je5ii6zFPwZ3_wewOfZhC_lC967DP_uxpP61-_7i8vvhZb39dbS6-b2vkQkCN1DcdaCmlMlyXm-pAoBLeM-VYCQitSUOMkIwZDdoBoPEMifGq4QjstNos3Dbi3t6lMGB6sBGDfQzEdGsxFWu9t1orFOBBNKLhjhAtqOMKJee6WOC6sL4trLtDM_jW-XFK2L-Cvs6MYWdv470t7qg0M-DLAnAp5px8d3xLwM5DsGUIdh6C1bP1zy_ljrX_W14KbpaCNITJutj33k0hjnmPU7bZY3I7G8YuPubnr7YxWGzyLMcYkc9JIqjSjFDKygFoQX9a0L5I-g6P4kpzxdizN-wHHHcvukAIAS7ZP5CwtHY</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Al-Hamadani , Aysha</creator><creator>Al-Busafi , Said A</creator><creator>Rasool , Wasif</creator><creator>Al-Suleimani , Abdulatif</creator><general>Oman Medical Specialty Board</general><general>OMJ</general><scope>~6Z</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170901</creationdate><title>Tenofovir-Induced Leukocytoclastic Vasculitis</title><author>Al-Hamadani , Aysha ; Al-Busafi , Said A ; Rasool , Wasif ; Al-Suleimani , Abdulatif</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a4550-a2ebf086667948a2e7f05a75ee37c38a25881b1956339808c00a9e3a19e7b4a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Case Report</topic><topic>Chronic active hepatitis</topic><topic>DIAGNOSIS</topic><topic>HEPATITIS</topic><topic>Hepatitis B</topic><topic>Leukocytoclastic Vasculitis</topic><topic>LIVER DISEASES</topic><topic>PATIENTS</topic><topic>Prevention</topic><topic>Tenofovir</topic><topic>THERAPY</topic><topic>Thrombotic thrombocytopenic purpura</topic><topic>VASCULITIS</topic><topic>أمراض الكبد</topic><topic>إلتهاب الأوعية</topic><topic>إلتهاب الكبد</topic><topic>التشخيص</topic><topic>العلاج</topic><topic>المرضى</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Hamadani , Aysha</creatorcontrib><creatorcontrib>Al-Busafi , Said A</creatorcontrib><creatorcontrib>Rasool , Wasif</creatorcontrib><creatorcontrib>Al-Suleimani , Abdulatif</creatorcontrib><collection>Al Manhal All Journals Collection</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oman medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Hamadani , Aysha</au><au>Al-Busafi , Said A</au><au>Rasool , Wasif</au><au>Al-Suleimani , Abdulatif</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tenofovir-Induced Leukocytoclastic Vasculitis</atitle><jtitle>Oman medical journal</jtitle><addtitle>Oman Med J</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>32</volume><issue>5</issue><spage>429</spage><epage>431</epage><pages>429-431</pages><issn>1999-768X</issn><eissn>2070-5204</eissn><abstract>Tenofovir, a nucleotide analog, is one of the first-line medications recommended for
the treatment of active chronic hepatitis B virus infection (CHB) and as a primary
prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report
the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese
woman, who was known to have inactive CHB, was diagnosed with chronic immune
thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was
put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a
skin rash, described as non-blanchable well-defined erythematous to violaceous papules
and targetoid patches in her lower extremities. A skin biopsy showed features of LCV.
The rash resolved completely within few days after replacing tenofovir with entecavir.</abstract><cop>Muscat - Oman</cop><pub>Oman Medical Specialty Board</pub><pmid>29026476</pmid><doi>10.5001/omj.2017.80</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1999-768X |
| ispartof | Oman medical journal, 2017-09, Vol.32 (5), p.429-431 |
| issn | 1999-768X 2070-5204 |
| language | eng |
| recordid | cdi_pubmed_primary_29026476 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Case Report Chronic active hepatitis DIAGNOSIS HEPATITIS Hepatitis B Leukocytoclastic Vasculitis LIVER DISEASES PATIENTS Prevention Tenofovir THERAPY Thrombotic thrombocytopenic purpura VASCULITIS أمراض الكبد إلتهاب الأوعية إلتهاب الكبد التشخيص العلاج المرضى |
| title | Tenofovir-Induced Leukocytoclastic Vasculitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T12%3A08%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tenofovir-Induced%20Leukocytoclastic%20Vasculitis&rft.jtitle=Oman%20medical%20journal&rft.au=Al-Hamadani%20,%20Aysha&rft.date=2017-09-01&rft.volume=32&rft.issue=5&rft.spage=429&rft.epage=431&rft.pages=429-431&rft.issn=1999-768X&rft.eissn=2070-5204&rft_id=info:doi/10.5001/omj.2017.80&rft_dat=%3Cpubmed_doaj_%3E29026476%3C/pubmed_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29026476&rft_informt_id=10.3316/informit.152783122352702&rft_doaj_id=oai_doaj_org_article_887a50e05b5b4c11852c47a6448f0848&rfr_iscdi=true |